Read by QxMD icon Read


Ofir Elalouf, Stephanie O Keeling, Zahi Touma
Systemic lupus erythematosus is a chronic autoimmune disease with various clinical manifestations, organ involvement and laboratory findings. The disease can involve any organ including skin, joints, kidneys, central and peripheral nervous system, cardiovascular system and more. Currently, the cornerstone of treatment includes antimalarial and immunosuppressive medications and glucocorticosteroids. Recently, great effort has been invested in finding more targeted drugs for achieving better control of the disease with less adverse events...
August 14, 2018: Immunotherapy
Marek Jutel, Michael Rudert, Fabian Kreimendahl, Piotr Kuna
AIM: This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation. OBJECTIVE: To evaluate four maintenance doses of the allergoid preparation versus placebo. METHODS: The late-phase reaction of the intracutaneous test was chosen as efficacy parameter and minimal dose of fluticasone required for asthma control...
August 9, 2018: Immunotherapy
Hans D Ochs, Isaac Melamed, Michael Borte, James N Moy, Barbara Pyringer, Ai Lan D Kobayashi, Alan P Knutsen, William Smits, Anna Pituch-Noworolska, Roger H Kobayashi
AIM: To assess the safety and efficacy of an intravenous immunoglobulin (IVIG) 10% preparation (Panzyga® ; Octapharma AG, Lachen, Switzerland) in predominantly antibody-deficient children with primary immunodeficiency disease. METHODS: Data from two prospective, open-label and noncontrolled multicenter Phase III studies of IVIG 10% that included 25 patients <16 years of age were analyzed for efficacy, pharmacokinetics and safety. RESULTS: The rate of serious bacterial infections was 0...
August 8, 2018: Immunotherapy
Christine Bangert, Tamara Kopp
Psoriasis is a chronic skin disorder driven by IL-23 and the downstream T-helper cell 17 (Th17) pathway. Tildrakizumab is a humanized monoclonal antibody selectively targeting the p19 subunit of IL-23, a key cytokine for Th17 cells. Here, we provide an overview of IL-23 in the context of psoriasis pathogenesis and review the results of the Phase I, II and III clinical trials for tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis in order to assess its efficacy, safety and clinical usefulness...
August 7, 2018: Immunotherapy
Renuka Sivendran, José Ramírez, Monica Ramchandani, Jennifer Liu
Analytical similarity is the foundation of the totality-of-evidence-based approach for demonstrating that a proposed biosimilar is highly similar to a reference product. This review uses analytical similarity assessment of ABP 501, the first approved adalimumab biosimilar, as a case study to highlight considerations necessary to demonstrate analytical similarity. Similarity assessments start with risk-ranking the critical quality attributes based on scientific understanding of how they impact safety, efficacy, immunogenicity and/or pharmacokinetics/pharmacodynamics...
August 3, 2018: Immunotherapy
Dandan Wang, Song Bai, Yulin Cui, Na Zhao, Feifei Qi, Jing Liu, Sheng Zeng, Lei Xu, Haiyan Hu, Beixing Liu
AIM: How respiratory syncytial virus (RSV) influences the development of ovalbumin (OVA)-induced asthma remains elusive. As potent T helper (Th)2 cytokine producers, group 2 innate lymphoid cells (ILC2s) are known to serve important functions in the pathogenesis of allergic inflammation. However, how RSV infection affects innate immunity, especially with regard to the function of ILC2s in OVA-induced allergic airway inflammation, is largely unknown. MATERIALS & METHODS: RSV was used to infect adult BALB/c mice intranasally prior to sensitization and subsequent challenge with OVA...
July 20, 2018: Immunotherapy
Pavan Tenneti, Mitesh J Borad, Hani M Babiker
The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14...
June 14, 2018: Immunotherapy
Laís Teodoro da Silva, Wanessa Cardoso da Silva, Alexandre de Almeida, Denise da Silva Reis, Bruna Tereso Santillo, Paula Ordonhez Rigato, Alberto José da Silva Duarte, Telma Miyuki Oshiro
AIMS: A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS: Monocytes obtained from 17 HIV-infected individuals were differentiated into MDDCs and, after loading with autologous HIV, the cells were characterized concerning surface molecule expression, migratory and phagocytosis capacity, cytokine production and the induction of an effective cell-mediated immune response...
August 2018: Immunotherapy
Taylor R Cushman, Mauricio S Caetano, James W Welsh, Vivek Verma
Given the unprecedentedly rapid progression of clinical immuno-oncology, evaluation of currently ongoing and upcoming clinical trials is essential to address potential deficiencies for future trial design. This observational study examined trends in the current landscape of clinical trials investigating immunotherapy with radiotherapy (iRT). The National Institute of Health's database was queried for trials including radiation and one of the six currently US FDA approved immunotherapy drugs: ipilimumab, nivolumab, pembrolizumab, durvalumab, atezolizumab and avelumab...
August 2018: Immunotherapy
Khalil Saleh, Nadine Khalifeh-Saleh, Hampig Raphael Kourie
No abstract text is available yet for this article.
August 2018: Immunotherapy
Ryota Tamura, Toshihide Tanaka, Yohei Yamamoto, Yasuharu Akasaki, Hikaru Sasaki
Macrophages are significant in immune responses, assuming a defensive role. In contrast, macrophages often cause undesirable changes. These reactions are processes by which macrophages express different functional programs in response to microenvironmental signals, defined as M1/M2 polarization. Tumor immunity has been acknowledged for contributing to the elucidation of the mechanism and clinical application in cancer therapy. One of the mechanisms for the refractoriness to cancer immunotherapy is the production of inhibitory cytokines by tumor cells or macrophages...
August 2018: Immunotherapy
Pauline Rochefort, Juliette Roussel, Arnaud de la Fouchardière, Matthieu Sarabi, Françoise Desseigne, Pierre Guibert, Anne Cattey-Javouhey, Charles Mastier, Eve-Marie Neidhardt-Berard, Christelle de la Fouchardière
Primary malignant melanoma of the esophagus is rare, accounting for less than 0.1-0.2% of all esophageal malignancies. It is associated with a poor outcome due to late detection and high metastatic potential. Here, we report a case of esophageal cancer, which was initially diagnosed as an adenocarcinoma and finally was confirmed as a primary malignant melanoma. This 75-year-old Caucasian male had a history of dysphagia and recent lingering abdominal pain. First biopsy showed a poorly-differentiated adenocarcinoma...
August 2018: Immunotherapy
Pedro Aguiar, Auro Del Giglio, Luke Alastair Perry, Jahan Penny-Dimri, Hani Babiker, Hakaru Tadokoro, Gilberto Lopes, Ramon Andrade De Mello
AIM: Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation. METHODS: The number of patients with non-small-cell lung cancer eligible for immunotherapy was estimated using local epidemiology data. We extracted survival data from RCTs to estimate the life-years saved in a 5-year time horizon. All costs were in local prices converted to US dollars. RESULTS: In the first-line, the budget impact of pembrolizumab decreased by 35% through risk-sharing...
August 2018: Immunotherapy
Ping Xu, Yu Pang, Junchi Xu, Hui Chen, Peijun Tang, Meiying Wu
In this report, we identified a multidrug-resistant tuberculosis (MDR-TB) patient who remained acid-fast bacilli culture positive despite aggressive WHO-directed therapy. Between July 2014 and February 2015, she received eight courses of cytokine-induced killer (CIK) cell-based adoptive cellular immunotherapy in combination to the second-line anti-TB treatment. This case achieved culture conversion, and experienced no relapse during 2-year follow-up under the treatment with CIK cell-based adoptive cellular immunotherapy...
August 2018: Immunotherapy
Sabrina Rossi, Angelo Castello, Luca Toschi, Egesta Lopci
The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) immunosuppressive pathway. Although patient's selection in the first-line setting relies essentially on high levels of PD-L1 tumor expression, treatment choice in pretreated patients is more challenging and, although clinical and biological characteristics might be of help, there is an urgent need for novel tools to better identify sensitive and resistant patients...
July 2018: Immunotherapy
Elie El Rassy, Marwan Ghosn, Nathalie Al Rassy, Tarek Assi, Caroline Robert
The interaction between the two recent hallmarks of carcinogenesis, the immune system and energetic metabolism, has not been well investigated. The limited literature available on this topic describes a correlation between the efficacy and safety of immune checkpoint inhibitors with body mass index. A key knowledge gap is the understanding of this correlation as outcomes are strongly affected highlighting the need to prospective studies in this regard. This paper evaluates the rationale to these correlations at weight extremes and suggests the evaluation patient's weights and associated inflammatory profile before the initiation of immune checkpoint inhibition in cancer patients...
July 2018: Immunotherapy
Jeremy B Foote, Leisha A Emens
No abstract text is available yet for this article.
July 2018: Immunotherapy
Dipongkor Saha, Robert L Martuza, Samuel D Rabkin
Oncolytic viruses, such as oncolytic herpes simplex virus (oHSV), are a new class of cancer therapeutic, which selectively replicate and kill cancer cells, while inducing an inflammatory microenvironment, immunovirotherapy. Recently, an oHSV (talimogene laherparepvec) has been approved for the treatment of advanced melanoma. Glioblastoma (GBM) is an almost always lethal primary tumor in the brain that is highly immunosuppressive, and posited to contain GBM stem-like cells (GSCs). Immune checkpoint blockade has revolutionized therapy for some cancers, but not GBM...
July 2018: Immunotherapy
T de Nattes, L Lelandais, I Etienne, C Laurent, D Guerrot, D Bertrand
Antithymocyte globulin is the most widely used lymphocyte-depleting treatment in kidney transplantation. In spite of the frequency of side effects, including anemia and thrombocytopenia, their pathophysiological mechanisms are not clearly established. Here, we report the case of a 21-year-old patient who had a first kidney transplantation and received induction immunosuppressive therapy by thymoglobulin. Immediately after kidney transplantation, he developed a severe hemolytic anemia and thrombocytopenia with a subsequent perirenal hematoma, which lead to a second surgical procedure and a transfer to the intensive care unit...
July 2018: Immunotherapy
Paola Circosta, Katia Vitaggio, Angela Rita Elia, Maja Todorovic, Dario Sangiolo, Fabrizio Carnevale-Schianca, Antonella Vallario, Massimo Geuna, Massimo Aglietta, Alessandro Cignetti
Allogeneic hematopoietic cell transplantation (allo-HCT) is an adoptive immunotherapy strategy whose effectiveness relies on graft-versus-tumor (GVT) effect. We explored the feasibility of enhancing GVT after allo-HCT by peptide vaccination. Two myeloma patients were transplanted with a fludarabine-total body irradiation conditioning regimen and vaccinated with an HLA-A*0201-restricted modified survivin nonapeptide, plus montanide as adjuvant. At time of first vaccination, one patient had just attained serological remission despite documented relapse after transplant, while the other patient was in stable disease...
July 2018: Immunotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"